Literature DB >> 16785519

IL-18 bridges innate and adaptive immunity through IFN-gamma and the CD134 pathway.

Joseph R Maxwell1, Rajwardhan Yadav, Robert J Rossi, Carl E Ruby, Andrew D Weinberg, Hector L Aguila, Anthony T Vella.   

Abstract

IL-18 induces inflammation resulting in either enhanced protection from pathogens or exacerbation of autoimmunity, and T cells are profoundly activated during these responses. How IL-18 influences T cell activation is unknown, but this study in mice shows that IL-18 boosted Ag-specific T cell clonal expansion of effector T cells and induced a subpopulation of IFN-gamma superproducing T cells. Commitment to IFN-gamma production through IL-18 was independent of NK cells and IL-12 but dependent on host-derived IFN-gamma. To determine how expansion of these effectors occurred, IL-18 was shown to induce OX40L on dendritic cells, whereas peptide stimulation induced CD134 (OX40) on specific T cells. CD134 blockade inhibited T cell effector expansion thereby reducing the number of IFN-gamma superproducers by 12-fold. Thus, independent of IL-12, IL-18 impacts T cell immunity throughout lymphoid and nonlymphoid tissue by bridging the innate and adaptive arms of the immune system through IFN-gamma and the CD134 costimulatory pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785519     DOI: 10.4049/jimmunol.177.1.234

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

Review 2.  T-cell activation in the intestinal mucosa.

Authors:  Dina Montufar-Solis; Tomas Garza; John R Klein
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

3.  Stimulatory and costimulatory effects of IL-18 directed to different small intestinal CD43 T cell subsets.

Authors:  Dina Montufar-Solis; Heuy-Ching Wang; John R Klein
Journal:  J Leukoc Biol       Date:  2007-08-16       Impact factor: 4.962

4.  Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Authors:  Paurvi Shinde; Wenhai Liu; Antoine Ménoret; Andrew D Luster; Anthony T Vella
Journal:  J Leukoc Biol       Date:  2017-04-21       Impact factor: 4.962

5.  The WSX-1 pathway restrains intestinal T-cell immunity.

Authors:  Jeremy P McAleer; Christiaan J M Saris; Anthony T Vella
Journal:  Int Immunol       Date:  2011-01-13       Impact factor: 4.823

6.  A role for IL-18 in protective immunity against Mycobacterium tuberculosis.

Authors:  Bianca E Schneider; Daniel Korbel; Kristine Hagens; Markus Koch; Bärbel Raupach; Jana Enders; Stefan H E Kaufmann; Hans-Willi Mittrücker; Ulrich E Schaible
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

7.  Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF.

Authors:  Jeremy P McAleer; Robert J Rossi; Anthony T Vella
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

8.  TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigens.

Authors:  Ramachandran Vignesh; Nagalingeswaran Kumarasamy; Andrew Lim; Suniti Solomon; Kailapuri G Murugavel; Pachamuthu Balakrishnan; Sunil S Solomon; Kenneth H Mayer; Chinnambedu R Swathirajan; Ezhilarasi Chandrasekaran; Ambrose Pradeep; Selvamuthu Poongulali; Constance A Benson; Martyn A French
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

Review 9.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

10.  Interleukin-18 binding protein in the sera of patients with Wegener's granulomatosis.

Authors:  D Novick; D Elbirt; C A Dinarello; M Rubinstein; Z M Sthoeger
Journal:  J Clin Immunol       Date:  2008-07-02       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.